Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhib...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of medicinal chemistry Ročník 51; číslo 18; s. 5843 - 5855
Hlavní autoři:	Summa, Vincenzo, Petrocchi, Alessia, Bonelli, Fabio, Crescenzi, Benedetta, Donghi, Monica, Ferrara, Marco, Fiore, Fabrizio, Gardelli, Cristina, Paz, Odalys Gonzalez, Hazuda, Daria J., Jones, Philip, Kinzel, Olaf, Laufer, Ralph, Monteagudo, Edith, Muraglia, Ester, Nizi, Emanuela, Orvieto, Federica, Pace, Paola, Pescatore, Giovanna, Scarpelli, Rita, Stillmock, Kara, Witmer, Marc V., Rowley, Michael
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	WASHINGTON Amer Chemical Soc 25.09.2008
Témata:	Administration, Oral Area Under Curve Biological Availability Chemistry, Medicinal Half-Life HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use Humans Life Sciences & Biomedicine Magnetic Resonance Spectroscopy Mass Spectrometry Pharmacology & Pharmacy Pyrrolidinones - administration & dosage Pyrrolidinones - pharmacokinetics Pyrrolidinones - pharmacology Pyrrolidinones - therapeutic use Raltegravir Potassium Science & Technology CELLS DESIGN DEPENDENT RNA-POLYMERASE REPLICATION 4,5-DIHYDROXYPYRIMIDINE ACIDS
ISSN:	0022-2623, 1520-4804, 1520-4804
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!